Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From R-Pharm JSC
Plus deals involving BioAtla/BeiGene, OliX/Thea, Chugai/Argenx, Shionogi/HanaVax, TaiGen/Luminairie, Novartis/1Yao.com, Sperogenix/Minoryx, Quantum/Orient EuroPharma and AtomWise/GC Pharma.
Novartis will take over development and commercialization of antisense candidate TQJ230 under rights it obtained in a 2017 agreement. Morphic and Janssen will collaborate on oral integrin inhibitors.
BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.
Turkey's TRPharm, in partnership with India's Dr Reddy's, has become the first company to gain a license for an oncology biosimilar Mab product in Turkey. Chairman Mehmet Göker spoke to Scrip about the company's international expansion plans.
- Diagnostic Equipment & Supplies
- Diagnostic Imaging Equipment & Supplies
- Monitoring Equipment & Devices
Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
- TR-Pharm (Turkey)
- R-PHARM US